Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape

Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders with heterogeneous presentation, ranging from indolent disease courses to aggressive diseases similar to acute myeloid leukemia (AML). Approximately 90% of MDS patients harbor recurrent mutations , which – with the exception of mutat...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwind, Sebastian, Jentzsch, Madlen, Kubasch, Anne Sophie, Metzeler, Klaus H., Platzbecker, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495032/
https://www.ncbi.nlm.nih.gov/pubmed/34601234
http://dx.doi.org/10.1016/j.neo.2021.09.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495032/
https://www.ncbi.nlm.nih.gov/pubmed/34601234
http://dx.doi.org/10.1016/j.neo.2021.09.002

Ejemplares similares